NMA: Nonprescription Medicines Academy

New Product Alerts

December 14th, 2012

“Tamper-Resistant” Pseudoephedrine
At least two immediate-release pseudoephedrine products designed to resist conversion to methamphetamine are expected to be available by the end of 2012. Nexafed (Acura Pharmaceuticals, Inc.) 30-mg tablets incorporate proprietary IMPEDE technology; results of a recent phase 1 pharmacokinetic study showed the tablets to be bioequivalent to Sudafed and a generic store brand. Additional information is available at acurapharm.com/NEXAFED/. Zephrex-D (Westport Pharmaceuticals) 30-mg tablets incorporate proprietary Tarex technology; the product currently is available in Missouri, with national distribution planned for 2013. Additional information is available at zephrex-d.com.

Abreva Conceal
The Abreva product line has been expanded to include Abreva Conceal, a clear, nonmedicated patch designed to be placed over cold sore blisters. The patch uses proprietary MicroAir technology that allows air in while keeping contaminants out; it can be left in place for up to 8 hours. Abreva Conceal is intended to serve as a protective barrier and provide a smooth surface for makeup application.

Omron electroTHERAPY Pain Relief
Omron Healthcare has introduced the electroTHERAPY Pain Relief unit, a portable nonprescription device that uses transcutaneous electrical nerve stimulation (TENS) technology. Self-adhesive pads attach by cords to the base unit; the pads are placed at least 1 inch apart near the site of acute pain to deliver gentle, massage-like pulses. The electroTHERAPY Pain Relief unit features three preset programs, each with five levels of intensity, for personalization according to the type of pain. The device may be used for 30 minutes per session up to three times daily. Additional information is available at the educational website www.omronpainrelief.com.

Flucelvax
The FDA has approved the first seasonal influenza vaccine licensed in the United States produced using cultured animal cells instead of fertilized chicken eggs. Flucelvax is approved to prevent seasonal influenza in adults 18 years of age or older. In a randomized, controlled trial that enrolled 7,700 people 18 to 49 years of age in the United States and Europe, Flucelvax was 83.8% effective in preventing influenza when compared to placebo.